



For Immediate Release

ChromaDex's Frank Jaksch to Speak at The X-Ceuticals Synergy Conference

IRVINE, CALIF., November 12, 2008 – Frank Jaksch, President and CEO of ChromaDex will be speaking at HBA Global Expo's **The X-Ceuticals Synergy Conference: *From Formulation to Novel Packaging Solutions*** on March 2-3, 2009 at the Hilton New York Hotel in NYC.

This unique conference is focusing on emerging trends of the synergy of cosmeceuticals and nutraceuticals being used alone and in combination to empower both technical and packaging perspectives. The title of the talk is **"THE NEXT SUPER-CLASS OF INGREDIENTS FOR FUNCTIONAL FOOD AND COSMETICS"**, which is on **Tuesday, March 3 at 11:30am-11:50am.**

As industry peers, we can all benefit from one another's experiences, insights and ideas. ChromaDex can offer its customers a **30% discount off the conference package price.** Use **PRIORITY CODE: SPKRG** by registering at www.accureg.com/hbas09/regprod.html

Please take this opportunity to support ChromaDex and sit in on some of the other wonderful talks over the course of the two days. For a full listing of the program, visit: www.hbaexpo.com/synergy.

About ChromaDex

ChromaDex is a leader in the development of Phytochemical and Botanical Reference Standards and the creation of associated intellectual property. ChromaDex is committed to sustainable "Green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the analytical tools and services to meet product regulatory, quality, efficacy and safety standards.

Forward-Looking Statements

Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to: the ability to market, produce and sell the referenced ingredients; risks relating to product and customer demand, market acceptance of our products; the effect of economic conditions both nationally and internationally; the ability to protect our intellectual property rights; the impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our ability to raise capital to fund continuing operations; the ability to complete transactions; and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

ChromaDex Corporation
 10005 Muirlands Blvd, Suite G
 Irvine, CA 92618
 Phone 949-419-0288
 Fax 949-419-0294
 Email info@chromadex.com
www.chromadex.com

Investor Inquiries:

Parag Dave
 Porter Novelli Life Sciences
 619-849-5378
pdave@pnlifesciences.com

Media Inquiries:

Megan Lavine
 Porter Novelli Life Sciences
 619-849-5388
mlavine@pnlifesciences.com

#

ChromaDex Corporation and Subsidiaries
Condensed Consolidated Statements of Operations (Unaudited)

	Three Months ended	
	September 27, 2008	September 29, 2007
Sales	\$ 1,069,003	\$ 1,194,575
Cost of goods sold	<u>881,839</u>	<u>752,390</u>
Gross profit	<u>187,164</u>	<u>442,185</u>
Operating expenses:		
Selling	178,439	100,986
General and administrative	<u>707,095</u>	<u>332,589</u>
	<u>885,534</u>	<u>433,575</u>
Operating (loss) income	<u>(698,370)</u>	<u>8,610</u>
Nonoperating (income) expenses:		
Interest expense	27,208	6,338
Interest income	<u>(12,154)</u>	<u>(423)</u>
Other	<u>(3,077)</u>	<u>(1,274)</u>
	<u>11,977</u>	<u>4,641</u>
Net (loss) income	<u>\$ (710,347)</u>	<u>\$ 3,969</u>
Basic and Diluted loss per common share	<u>\$ (0.02)</u>	<u>\$ 0.00</u>
Basic and Diluted average common shares outstanding	<u>28,600,943</u>	<u>22,039,664</u>